Overview: Cysticercosis IgG TestIntroduction: The Cysticercosis IgG Test detects IgG antibodies to Taenia solium, indicating cysticercosis causing seizures or muscle pain. Aligned with 2023 IDSA guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in serology for patients with suspected cysticercosis.
Other Names: Taenia Solium IgG Assay, Cysticercosis Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: Cysticercosis antibody testing began in the 1980s with parasitic research. Immunoassays emerged in the 1990s, and by the 2000s, high-sensitivity assays improved accuracy.
Purpose: Diagnoses cysticercosis, guides antiparasitic therapy, and monitors antibody presence in patients with seizures or muscle pain.
Test Parameters: 1. Taenia Solium IgG
Pretest Condition: No fasting required. Collect serum, CSF, or saliva at any time. Report symptoms like seizures or muscle pain, and list recent travel or pork consumption.
Specimen: 2-5 mL serum (SST), 1-2 mL CSF (sterile container), or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document seizures, muscle pain, or recent travel to endemic areas. Include current medications, especially antiparasitics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antiparasitic therapy.
Procedural Considerations: Uses an immunoassay to detect Taenia solium IgG antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Cross-reactivity with other parasites may cause false positives. Early infection may cause false negatives.
Clinical Significance: Positive IgG results suggest cysticercosis, prompting antiparasitic therapy. Negative results may require imaging or PCR.
Specialist Consultation: Consult an infectious disease specialist or neurologist for result interpretation.
Additional Supporting Tests: Brain imaging, CSF analysis, or cysticercosis PCR to confirm infection.
Test Limitations: False positives may occur with related parasites. Results require clinical correlation.
References: IDSA Cysticercosis Guidelines, 2023; Clinical Infectious Diseases, Garcia HH, 2022.
